Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
- NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investor Conference on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
- 09/03/2024
|
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Alex Braun - Head of Investor Relations Conference Call Participants Tom Shrader - BTIG Cameron Bozdog - Bank of America Samantha Schaeffer - Cantor Fitzgerald Trung Huynh - UBS Ananda Ghosh - HC Wainwright Operator Hello, and thank you for standing by.
- 08/13/2024
|
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
- NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2024 financial results on Tuesday, August 13, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
- 08/06/2024
|
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
- Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug's Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease.
- 07/29/2024
|
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease
- NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer's disease (AD), today announced that the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison study. The study plans to compare the PK between subcutaneous and intravenous administrations of sabirnetug in healthy volunteers.
- 07/29/2024
|
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024
- NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193). The research highlights the experiences of patients in the clinical trial to inform development of future trials, biomarker data to support sabirnetug's mechanism of action, and an ultra-sensitive method of measuring small amounts of sabirnetug in cerebrospinal fluid (CSF). The posters will be presented at the Alzheimer's Association International Conference (AAIC®) 2024 taking place in Philadelphia and online from July 28-Aug. 1, 2024.
- 07/28/2024
|
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Alex Braun - Vice President & Head of Investor Relations Daniel O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer & Chief Business Officer Eric Siemers - Chief Medical Officer Conference Call Participants Tom Shrader - BTIG Samantha Schaeffer - Cantor Fitzgerald Jason Zemansky - Bank of America Operator Good day and thank you for standing by. Welcome to Acumen Pharmaceuticals First Quarter 2024 Conference Call and Webcast.
- 05/14/2024
|
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
- CHARLOTTESVILLE, Va., May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.
- 05/14/2024
|
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.
- 05/13/2024
|
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
- CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).
- 05/08/2024
|
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease
- CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.
- 05/08/2024
|
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
- CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
- 05/07/2024
|
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
- CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver on April 16, 2024. The results build upon Acumen's prior presentations at the AD/PD™ 2024 Annual Meeting and positive topline data first announced in July 2023 and will be presented together for the first time with expanded analysis.
- 04/16/2024
|
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease
- CHARLOTTESVILLE, Va. and BASEL, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), has signed a collaboration agreement with Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets. The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble AβOs for the treatment of AD, for clinical development and commercialization, if approved.
- 04/04/2024
|
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
- Acumen Pharmaceuticals (ABOS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 04/03/2024
|
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
- Acumen Pharmaceuticals (ABOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 03/28/2024
|
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
- CHARLOTTESVILLE, Va., March 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2023 and provided a business update.
- 03/26/2024
|
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
- Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.
- 03/21/2024
|
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
- CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
- 03/19/2024
|
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
- CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat as part of the Stifel 2024 CNS Days on Tuesday, March 19, 2024, at 12:00 p.m. ET.
- 03/12/2024
|
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting
- - Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the brain in early AD
- 03/08/2024
|
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
- Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
- 02/29/2024
|
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting
- - Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD
- 02/21/2024
|
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
- CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O'Connell, Chief Executive Officer. Dr. Doherty's responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls and regulatory functions.
- 02/01/2024
|
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
- As investors, we are often looking to diversify our portfolios. Especially with the wild AI craze in the past year, many investors already hold positions in AI or other technology companies.
- 01/30/2024
|
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
- Aging stocks (or longevity stocks) are drawing attention from investors for obvious reasons. The Baby Boomer generation is now almost fully retired, and Gen X is right on its heels.
- 01/24/2024
|
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will present at the 42nd Annual J.P.
- 01/04/2024
|
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's During Symposium at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD)
- CHARLOTTESVILLE, Va. and INDIANAPOLIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it will present deeper insights and new exploratory findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-directed antibody therapy for early AD, at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Boston and online from October 24-27, 2023. INTERCEPT-AD was selected to be featured in a symposium on Friday, October 27, and data from exploratory analyses of the Phase 1 trial will also be shared in two in-person and two virtual poster presentations.
- 10/04/2023
|
Navigating Acumen's Alzheimer's Risk And Reward
- Acumen Pharmaceuticals' ACU193 shows promise as a potential treatment for early-stage Alzheimer's Disease, targeting amyloid beta oligomers with a more favorable safety profile. Q2 earnings show increased operating expenses and a net loss expansion, but a recent capital injection extends the cash runway and lowers the threat of near-term dilution. Market sentiment is cautious, but the Phase 1 results and financial stability suggest a potential buying opportunity for risk-tolerant investors.
- 10/03/2023
|
Acumen Pharmaceuticals: Novel Alzheimer's Molecule With Positive Early Data
- Acumen Pharmaceuticals is developing a monoclonal antibody, ACU193, that targets Amyloid beta oligomers (AβOs) in Alzheimer's disease. AβOs are small, soluble aggregates of amyloid-beta peptides that are believed to be more toxic to neurons than amyloid plaques. ACU193 demonstrated proof-of-mechanism in a phase 1 trial, showing significant reduction in amyloid plaques and a favorable safety profile. A phase 2/3 trial is planned for next year.
- 10/03/2023
|
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
- CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a panel discussion at the Cantor Global Healthcare Conference on Tuesday, Sept. 26, 2023 at 9:20 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
- 09/19/2023
|
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
- Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Haemonetics (HAE) have performed compared to their sector so far this year.
- 09/18/2023
|
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
- CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, Sept. 13, 2023 at 10:30 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
- 09/06/2023
|
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
- CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease, today announced that the Company will report second quarter financial results on Tuesday, August 8, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
- 08/01/2023
|
Acumen Soars on Alzheimer's Study
- Two years removed from an IPO, Acumen Pharmaceuticals, Inc. NASDAQ: ABOS looks like it made a good decision to go public. Shares of the Charlottesville, Virginia-based biotechnology company skyrocketed as much as 80% in Monday morning trading after it reported encouraging Alzheimer's disease study results.
- 07/19/2023
|
Why Shares of Acumen Pharmaceuticals Are Down Tuesday
- Acumen's shares rose more than 54% on Monday on positive trial news. Investors were likely taking profits Tuesday.
- 07/18/2023
|
Acumen: A First In Targeting, May Lead To Improvement For Early AD Patients
- Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market for Alzheimer's disease treatments is expected to rise past $13 billion by 2030. There was statistically significant amyloid plaque reduction observed with higher doses of ACU193 in the phase 1 INTERCEPT-AD study; statistically significant plaque reduction observed with a p-value of p=0.01.
- 07/18/2023
|
Why Is Acumen Pharmaceuticals (ABOS) Stock Up 46% Today?
- Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is on the rise Monday after the company released data from a Phase 1 clinical trial. This data comes from the company's Phase 1 INTERCEPT-AD trial of ACU193.
- 07/17/2023
|
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease
- Company to host conference call and webcast for investors and analysts today, July 17, at 8 a.m. ET Company to host conference call and webcast for investors and analysts today, July 17, at 8 a.m. ET
- 07/17/2023
|
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Call Transcript
- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO and Chief Business Officer Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - BofA Operator Good day, and thank you for standing by. Welcome to the Acumen Pharma Q1 2023 Conference Call and Webcast.
- 05/14/2023
|
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
- CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
- 05/02/2023
|
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2022 Earnings Call Transcript
- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and Chief Executive Officer Eric Siemers - , Chief Medical Officer Matt Zuga - Chief Financial Officer and Chief Business Office Conference Call Participants Paul Matteis - Stifel Tom Shrader - BTIG Judah Frommer - Credit Suisse Operator Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2022 Conference Call and Webcast.
- 03/27/2023
|
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
- CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2022 financial results on Monday, March 27, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
- 03/20/2023
|
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q3 2022 Results - Earnings Call Transcript
- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - CMO Matt Zuga - CFO and CBO Conference Call Participants Tom Shrader - BTIG Judah Frommer - Credit Suisse Charlie Yang - Bank of America Operator Good day. Thank you for standing by.
- 11/14/2022
|
Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022
- CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease, today announced that the Company will report its financial results for the third quarter 2022 on Monday, November 14, 2022. The Company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.
- 11/07/2022
|
Trading Ideas On The Upcoming CTAD 2022 Conference
- The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
- 11/02/2022
|
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
- Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
- 10/21/2022
|
Why Is Acumen (ABOS) Stock Up 95% Today?
- Source: pathdoc / Shutterstock.com Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is rocketing higher on Wednesday but it's not due to any news from the company. Instead, investors have Biogen (NASDAQ: BIIB ) to thank for the increase of ABOS stock's price.
- 09/28/2022
|
4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes
- Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/28/2022
|
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q2 2022 Results - Earnings Call Transcript
- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants John Woolford - Investor Relations, Westwicke Daniel O'Connell - President & Chief Executive Officer Eric Siemers - Chief Medical Officer Matt Zuga - Chief Financial Officer & Chief Business Officer Conference Call Participants Judah Frommer - Credit Suisse Tom Shrader - BTIG Ting Liu - UBS Operator Good day. Thank you for standing by, and welcome to the Acumen Pharmaceuticals, Second Quarter 2022 Update Call.
- 08/15/2022
|
Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022
- CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the Company will report its financial results for the second quarter 2022 on Monday, August 15, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.
- 08/08/2022
|
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q1 2022 Results - Earnings Call Transcript
- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants John Woolford - IR, Westwicke Daniel O'Connell - President & CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Operator Operator Thank you for standing by, and welcome to the Acumen Pharmaceuticals, First Quarter 2022 Update Call. At this time, all participants are in a listen-only mode.
- 05/16/2022
|
Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022
- CHARLOTTESVILLE, Va. and CARMEL, Ind., May 11, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the company will report its financial results for the first quarter 2022 on Monday, May 16, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.
- 05/11/2022
|
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q4 2021 Results - Earnings Call Transcript
- Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q4 2021 Results - Earnings Call Transcript
- 03/28/2022
|
Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
- CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the company will report its financial results for the fourth quarter and full year 2021 on Monday, March 28, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.
- 03/16/2022
|
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights
- CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today reported financial results for the quarter ended June 30, 2021 and provided recent business highlights.
- 08/16/2021
|
5 Stocks With High Insider Cluster Buys During July
- According to the Insider Cluster Buys Screen, a Premium feature of Gurus, five stocks with high number of unique insider buys during the past month include German American Bancorp Inc. ( GABC , Financial), Simon Property Group Inc. ( SPG , Financial), Partners Bancorp ( PTRS , Financial), Ames National Corp. ( ATLO , Financial) and Acumen Pharmaceuticals Inc. ( ABOS , Financial).
- 07/27/2021
|
The 5 biggest insider stock buys of last week
- Here are the five companies that saw the biggest combined stock purchases from insiders during the week ended July 9.
- 07/12/2021
|
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
- CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer's disease, today announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to Acumen, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $160 million. All of the shares of common stock are being offered by Acumen. In addition, Acumen has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
- 06/30/2021
|
Acumen Pharmaceuticals Pursues $125 Million IPO
- Acumen Pharmaceuticals has filed proposed terms for a $125 million IPO. The firm is developing a treatment for Alzheimer's Disease.
- 06/30/2021
|
